Cancer Center Support Grant

项目概要-总体 俄亥俄州州立大学综合癌症中心（OSUCCC）是在其第44个年头作为一个NCI指定 综合癌症中心，在其最近两次审查中获得了“特殊”的整体优点描述， 2010年和2015年，并要求在未来五年继续获得联邦支持。OSUCCC使命 通过基础、人口、转化和临床研究，降低癌症发病率和死亡率。 通过深思熟虑的战略规划，关注集水区（俄亥俄州）的癌症负担， 有效的组织能力和有针对性的投资，主任和他的高级领导团队将 使OSUCCC能够与地方，国家和全球合作伙伴一起推进合作癌症研究， OSUCCC最优先的举措。目前，293名正式成员和入门成员由以下人员担任： 16个完整的和两个发展中的共享资源，并分布在我们的五个研究计划：癌症 生物学（原分子生物学和癌症遗传学），癌症控制，白血病研究，分子 致癌作用、化学预防和转化治疗。OSUCCC促进合作基础 研究和实施战略，推进并将早期发现转化为临床和基于人群的 研究和解决我们的集水区的需求，通过研究，参与和推广，从 通过预防、治疗和生存来了解我们流域主要癌症的病因 地区人口。OSUCCC通过以下方式培训下一代以癌症为重点的科学家和临床医生： 新的和已建立的计划侧重于整合培训合作研究工作。下 领导的新主任，拉斐尔波洛克，医学博士，博士，OSUCCC支持创新的研究工作 在四个战略规划优先事项：免疫肿瘤学，癌症工程，转化基因组学和 癌症预防和生存。自上次CCSG竞争性更新以来，OSUCCC显示 显著增长表现在：1）招聘了108名基础、人口和转化科学教师 2）增加94，647平方英尺的研究和行政空间，完全控制 3）直接与癌症相关的资金增加16%，达到7540万美元，其中4430万美元来自 来自NCI; 4）14，996例患者参与干预性临床试验（5，648例参与治疗性试验）; 5） 增加了合作和有影响力的研究，3，477篇同行评审的出版物证明了这一点，其中74% 的手稿是多机构的，85%是合作的（即，方案间、方案内或多方案 机构）; 497篇发表在影响因子>10的期刊上; 6）增加了两个新的共享资源 机构投资130万美元; 7）FDA批准药物的临床前和临床开发 这改变了慢性淋巴细胞白血病和其他血癌的治疗方法。有了新成员和强大的机构 和慈善支持到位，OSUCCC正在建立的势头，并准备在未来五年 我们将在今后几年采取重大步骤，实现我们的使命和我们生活在一个无癌症世界的广阔愿景。

PROJECT SUMMARY – OVERALL The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated comprehensive cancer center, having received an “exceptional” overall merit descriptor in its last two reviews in 2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research. Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio), effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will enable the OSUCCC to advance collaborative cancer research with local, national and global partners on initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by 16 full and two developing shared resources and are distributed among our five Research Programs: Cancer Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic research and implements strategies that advance and translate early discovery into clinical and population-based research and addresses the needs of our catchment area through research, engagement and outreach, from etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through new and established programs focused on integrating training for collaborative research efforts. Under the leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5) increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74% of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi- institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.